Inflammation and prostate cancer: A future target for prevention and therapy?

被引：35

作者：

Stock, David ^{[2
,3
]}

Groome, Patti A. ^{[2
,3
]}

Siemens, D. Robert ^{[1
,4
]}

机构：

[1] Queens Univ, Kingston Gen Hosp, Dept Urol, Kingston, ON K7L 2V7, Canada

[2] Queens Univ, Dept Community Hlth & Epidemiol, Kingston, ON K7L 2V7, Canada

[3] Queens Univ, Queens Canc Res Inst, Div Canc Care & Epidemiol, Kingston, ON K7L 2V7, Canada

[4] Queens Univ, Dept Anat & Cell Biol, Kingston, ON K7L 2V7, Canada

来源：

UROLOGIC CLINICS OF NORTH AMERICA | 2008年 / 35卷 / 01期

关键词：

D O I：

10.1016/j.ucl.2007.09.006

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Given its long natural history, prostate cancer has become an ideal model for the clinical and basic science study of neoplastic disease in distinct pathologic phases: tumor initiation, progression, invasion, and metastasis. Chronic or recurrent acute inflammation, a product of infectious agents or other sources, has potential promotional roles in each of these phases. Nonsteroidal anti-inflammatory drugs (NSAIDs), because of their ability to attenuate inflammation, as well as possibly direct anti-cancer properties associated with the inhibition of stromal cyclooxygenase-2, are potential candidates for clinical use in prostate cancer. Though epidemiologic evidence indicating a reduced risk of prostate cancer for NSAID users supports a chemoprotective benefit, observational assessment and clinical trials of these agents among large cohorts of prostate cancer patients are needed to determine their value in prostate cancer management.

引用

页码：117 / +

页数：15

共 122 条

[1] Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells [J].